188 related articles for article (PubMed ID: 20527532)
1. A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models.
Bednarz B; Athar B; Xu XG
Med Phys; 2010 May; 37(5):1987-94. PubMed ID: 20527532
[TBL] [Abstract][Full Text] [Related]
2. Calculated organ doses from selected prostate treatment plans using Monte Carlo simulations and an anatomically realistic computational phantom.
Bednarz B; Hancox C; Xu XG
Phys Med Biol; 2009 Sep; 54(17):5271-86. PubMed ID: 19671968
[TBL] [Abstract][Full Text] [Related]
3. Exposure of remote organs and associated cancer risks from tangential and multi-field breast cancer radiotherapy.
Simonetto C; Rennau H; Remmele J; Sebb S; Kundrát P; Eidemüller M; Wolf U; Hildebrandt G
Strahlenther Onkol; 2019 Jan; 195(1):32-42. PubMed ID: 30350118
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo study of organ doses and related risk for cancer in Algeria from scattered neutrons in prostate treatment involving 3D-CRT.
Alem-Bezoubiri A; Suleiman SA; Behidj I; Mazrou H; Chami AC
Appl Radiat Isot; 2022 Feb; 180():110065. PubMed ID: 34933226
[TBL] [Abstract][Full Text] [Related]
5. A critical evaluation of secondary cancer risk models applied to Monte Carlo dose distributions of 2-dimensional, 3-dimensional conformal and hybrid intensity-modulated radiation therapy for breast cancer.
Joosten A; Bochud F; Moeckli R
Phys Med Biol; 2014 Aug; 59(16):4697-722. PubMed ID: 25082795
[TBL] [Abstract][Full Text] [Related]
6. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.
Murray LJ; Thompson CM; Lilley J; Cosgrove V; Franks K; Sebag-Montefiore D; Henry AM
Phys Med Biol; 2015 Feb; 60(3):1237-57. PubMed ID: 25590229
[TBL] [Abstract][Full Text] [Related]
7. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer.
Fontenot JD; Lee AK; Newhauser WD
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):616-22. PubMed ID: 19427561
[TBL] [Abstract][Full Text] [Related]
8. Constituent components of out-of-field scatter dose for 18-MV intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy: a comparison with 6-MV and implications for carcinogenesis.
Ruben JD; Smith R; Lancaster CM; Haynes M; Jones P; Panettieri V
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):645-53. PubMed ID: 25084609
[TBL] [Abstract][Full Text] [Related]
9. Monte Carlo determination of radiation-induced cancer risks for prostate patients undergoing intensity- modulated radiation therapy.
Stathakis S; Li J; Ma CCM
J Appl Clin Med Phys; 2007 Sep; 8(4):14-27. PubMed ID: 18449157
[TBL] [Abstract][Full Text] [Related]
10. Secondary cancer risk after radiation therapy for breast cancer with different radiotherapy techniques.
Zhang Q; Liu J; Ao N; Yu H; Peng Y; Ou L; Zhang S
Sci Rep; 2020 Jan; 10(1):1220. PubMed ID: 31988348
[TBL] [Abstract][Full Text] [Related]
11. Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy.
Kry SF; Salehpour M; Titt U; White RA; Stovall M; Followill D
Radiother Oncol; 2009 Apr; 91(1):132-7. PubMed ID: 19147246
[TBL] [Abstract][Full Text] [Related]
12. The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy, IMRT and VMAT for pediatric patients with brain tumors.
Moteabbed M; Yock TI; Paganetti H
Phys Med Biol; 2014 Jun; 59(12):2883-99. PubMed ID: 24828559
[TBL] [Abstract][Full Text] [Related]
13. A prediction study on radiation-induced second malignancies for IMRT treatment delivery.
Stathakis S; Roland T; Papanikolaou N; Li J; Ma C
Technol Cancer Res Treat; 2009 Apr; 8(2):141-8. PubMed ID: 19334795
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of organ-specific peripheral doses after 2-dimensional, 3-dimensional and hybrid intensity modulated radiation therapy for breast cancer based on Monte Carlo and convolution/superposition algorithms: implications for secondary cancer risk assessment.
Joosten A; Matzinger O; Jeanneret-Sozzi W; Bochud F; Moeckli R
Radiother Oncol; 2013 Jan; 106(1):33-41. PubMed ID: 23351844
[TBL] [Abstract][Full Text] [Related]
15. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field.
Paganetti H; Athar BS; Moteabbed M; A Adams J; Schneider U; Yock TI
Phys Med Biol; 2012 Oct; 57(19):6047-61. PubMed ID: 22968191
[TBL] [Abstract][Full Text] [Related]
16. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies.
Ruben JD; Davis S; Evans C; Jones P; Gagliardi F; Haynes M; Hunter A
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1530-6. PubMed ID: 18207670
[TBL] [Abstract][Full Text] [Related]
17. Calculated organ doses using Monte Carlo simulations in a reference male phantom undergoing HDR brachytherapy applied to localized prostate carcinoma.
Candela-Juan C; Perez-Calatayud J; Ballester F; Rivard MJ
Med Phys; 2013 Mar; 40(3):033901. PubMed ID: 23464344
[TBL] [Abstract][Full Text] [Related]
18. Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer.
Donovan EM; James H; Bonora M; Yarnold JR; Evans PM
Med Phys; 2012 Oct; 39(10):5814-24. PubMed ID: 23039620
[TBL] [Abstract][Full Text] [Related]
19. EVALUATION OF SECONDARY DOSE AND CANCER RISK FOR OUT-OF-FIELD ORGAN IN ESOPHAGEAL CANCER IMRT IN A CHINESE HOSPITAL USING ATOM PHANTOM MEASUREMENTS.
Qi Y; He L; Wang Z; Liu Y; Liu H; Huo W; Xu XG; Chen Z
Radiat Prot Dosimetry; 2017 Dec; 177(4):389-396. PubMed ID: 28472430
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT.
Lee B; Lee S; Sung J; Yoon M
J Radiol Prot; 2014 Jun; 34(2):325-31. PubMed ID: 24705154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
